Endocrinology market trends signal growing competition around treatment access, convenience and long-term outcomes, as continuous glucose monitoring expands, at-home endocrine therapies advance, rare disease evidence develops and regenerative diabetes platforms pursue durable clinical benefit.
Coverage Period: September 29 to November 2, 2026
Introduction
October’s 2026 defining endocrinology market development was the convergence of stronger evidence for expanding diabetes technology access, a new at-home treatment option in thyroid eye disease, and emerging platforms designed to reduce the burden of lifelong therapy.
These developments highlight a competitive shift in which clinical efficacy remains essential, but treatment accessibility, administration convenience, and long-term patient outcomes are becoming more important sources of differentiation. The period also exposed different levels of commercial readiness: established technologies are pursuing wider adoption, approved therapies are entering new treatment settings, and regenerative approaches remain focused on overcoming fundamental clinical barriers.
Companies covered: Dexcom, Tandem Diabetes Care, Roche, OPKO Health, Neurocrine Biosciences, Xeris Biopharma, Seraxis, Sernova Diseases covered: Type 2 diabetes, Type 1 diabetes, Congenital adrenal hyperplasia, Acromegaly, Thyroid eye disease
Executive Summary
- Diabetes technology is moving into broader patient populations and international markets. Dexcom’s CONNECT trial strengthened the clinical case for continuous glucose monitoring (CGM) in adults with type 2 diabetes not using insulin, while Tandem Diabetes Care expanded its Mobi automated insulin delivery system into 12 markets outside the United States. Reimbursement, interoperability, and commercial execution will shape further adoption.
- Treatment administration is becoming an important competitive factor in rare endocrine diseases. FDA approval of Roche’s subcutaneous Enspryng for thyroid eye disease introduces an at-home alternative to infusion-based treatment. OPKO’s investigational once-weekly growth hormone receptor antagonist for acromegaly reflects similar interest in reducing treatment burden, although its clinical benefits remain unproven.
- Longitudinal evidence is expanding how treatment value is assessed. Neurocrine’s congenital adrenal hyperplasia research documented evolving clinical and daily-life challenges, while Xeris highlighted gaps in emergency glucagon prescribing and real-world endocrine disease management. These findings may inform patient support, medical education, and evidence-generation strategies.
- Regenerative medicine development is placing greater emphasis on integrated platforms. The proposed Seraxis–Sernova merger combines stem cell-derived pancreatic islets with an implantable delivery system. The approach addresses important cell supply and engraftment challenges, but immune rejection, clinical durability, and scalability remain unresolved.
Watch the video summary
Our Strategic Perspective on Four Competitive Shifts in the Endocrinology Market
Continuous Glucose Monitoring Expands the Type 2 Diabetes Market Opportunity
New clinical evidence is strengthening the case for using continuous glucose monitoring earlier in type 2 diabetes management, extending its potential role beyond insulin-treated populations.
Dexcom’s CONNECT randomized trial reported a 1.6-percentage-point HbA1c reduction among CGM users, representing a 0.9-percentage-point greater improvement than routine care. Participants also spent approximately five additional hours daily within the target glucose range. Benefits were observed across multiple patient characteristics and treatment regimens, including GLP-1 therapy.
The strategic importance lies in the possibility of expanding CGM use within primary care, where a much larger population of non-insulin-treated patients could become eligible for monitoring technology.
At the same time, Tandem Diabetes Care’s expansion of Mobi into 12 international markets demonstrates how automated insulin delivery competition is extending geographically. Its integration with Dexcom G7 highlights the commercial relevance of connected device ecosystems and interoperability.
These developments represent distinct growth opportunities: broader CGM utilization among non-insulin-treated patients and wider international adoption of automated insulin delivery among eligible users.
Market implications: Evidence quality, payer coverage, geographic availability, and device compatibility may become increasingly important competitive differentiators. Clinical adoption will depend on translating trial outcomes into practical treatment pathways and sustainable reimbursement.
Key uncertainty: CONNECT supports clinical benefit over 26 weeks, but the extent of reimbursement expansion, long-term utilization, and uptake in routine primary care remains uncertain.
Subcutaneous and Long-Acting Endocrine Therapies Compete on Treatment Burden
Reducing administration burden is emerging as a meaningful route to differentiation in chronic endocrine disorders, particularly where established treatment pathways require repeated healthcare visits or ongoing injections.
The FDA approval of Roche’s Enspryng (satralizumab) for thyroid eye disease introduces an at-home subcutaneous treatment option, with maintenance administration every four weeks. This creates a different treatment experience from infusion-based approaches and could influence patient preference and prescribing decisions.
The clinical evidence requires a balanced interpretation. SatraGO-2 demonstrated meaningful improvements in proptosis and diplopia, while SatraGO-1 did not meet its prespecified primary efficacy endpoint. The commercial opportunity therefore rests on the combined assessment of efficacy, safety, convenience, and access rather than administration route alone.
A related approach is emerging in acromegaly. OPKO Biologics initiated a Phase 1/2a trial of OPK-8801001, an investigational growth hormone receptor antagonist engineered for potential once-weekly administration.
Rather than introducing an entirely new therapeutic pathway, the program seeks to improve the delivery characteristics of an established mechanism.
Market implications: Administration setting and dosing frequency could influence treatment selection, patient experience, and differentiation among therapies with established biological targets. Developers will need evidence that convenience does not compromise clinical outcomes.
Key uncertainty: Enspryng’s uptake will depend partly on clinician confidence, access, and its positioning against existing treatments. OPK-8801001 has not yet demonstrated its intended weekly dosing profile, clinical efficacy, or long-term safety in humans.
Congenital Adrenal Hyperplasia and Rare Endocrine Care Demand Longitudinal Evidence
Rare endocrine disease development is placing greater attention on treatment outcomes that extend beyond biochemical measurements and short clinical observation periods.
Neurocrine Biosciences presented a longitudinal analysis of classic congenital adrenal hyperplasia (CAH), drawing on more than 300 patient-years of medical history from 10 adults. The research captured changing needs across childhood, adolescence, and adulthood, including treatment management, reproductive health, care transitions, and disruptions to everyday activities.
The findings highlight an important limitation of conventional clinical assessments: hormone control alone may not fully characterize the burden of lifelong endocrine disease.
Neurocrine also highlighted two-year findings from its crinecerfont program, including sustained glucocorticoid dose reductions and clinical outcomes. Together, these efforts strengthen the relevance of long-term evidence to treatment evaluation.
Xeris Biopharma’s research provides another perspective. Its disclosures identified gaps between clinician awareness of ready-to-use glucagon guidelines and actual prescribing practices, alongside investigations into cortisol management in Cushing’s syndrome and monitoring patterns in hypothyroidism.
These examples underscore how unmet needs can persist even when effective therapies or established management guidelines are available.
Market implications: Longitudinal registries, prescribing-pattern research, and patient-centered outcomes may help companies improve medical education, identify care gaps, and demonstrate treatment value beyond immediate biochemical response.
Key uncertainty: Neurocrine’s patient-journey analysis was descriptive and involved only 10 individuals. Its findings cannot establish population-level estimates, while broader clinical and commercial implications require further validation.
Stem Cell-Derived Islet Therapy Moves Toward Integrated Type 1 Diabetes Platforms
In type 1 diabetes regenerative medicine, the challenge is shifting from producing insulin-secreting cells alone toward developing complete systems capable of supporting durable cell function.
The proposed merger between Seraxis and Sernova illustrates this direction. The planned BetaNova Biotherapeutics platform would combine Seraxis’ stem cell-derived pancreatic islet manufacturing capabilities with Sernova’s implantable Cell Pouch technology.
The combination addresses two critical development barriers: generating a scalable supply of therapeutic cells and providing an environment that supports their survival and function.
However, cell delivery does not resolve immune rejection. The initial SR-02 approach requires immunosuppression, while the proposed SR-03 program aims to investigate gene-edited cells designed to reduce immune recognition.
This creates a staged development strategy, prioritizing initial clinical validation while pursuing approaches that could eventually reduce dependence on chronic immunosuppressive treatment.
Market implications: Competitive advantage in regenerative diabetes therapies may depend on combining cell manufacturing, implantation technology, immune management, and reproducible clinical outcomes. Business combinations may offer a route to assembling these capabilities.
Key uncertainty: The planned platform has not yet established durable clinical efficacy as an integrated treatment. Successful merger completion, trial execution, immune protection, manufacturing scalability, and long-term safety remain essential milestones.
What We Are Watching Next in Endocrinology Market Competition
- CGM coverage and primary care adoption: Payer decisions and clinical practice changes following CONNECT will indicate how far CGM can expand within non-insulin-treated type 2 diabetes.
- Enspryng’s thyroid eye disease launch: Early prescribing patterns, reimbursement decisions, and physician acceptance will help establish the commercial value of at-home subcutaneous administration.
- Long-acting acromegaly treatment development: Initial OPK-8801001 clinical findings will be important for assessing safety, IGF-1 suppression, and the feasibility of once-weekly dosing.
- Type 1 diabetes cell therapy milestones: The proposed Seraxis–Sernova merger, anticipated SR-02 trial initiation in early 2027, and subsequent immune-evasion development will test the integrated platform strategy.
- Rare endocrine disease evidence generation: Further longitudinal and real-world studies could clarify how patient burden, treatment adherence, and care gaps influence clinical and commercial decision-making.
Key Takeaway: Access, Durability and Execution Shape Endocrinology Competition
October’s endocrinology developments reveal an important distinction between therapeutic innovation and the ability to deliver sustainable clinical value.
CGM evidence is opening opportunities for earlier intervention, while at-home and long-acting therapies are making treatment convenience a more visible competitive consideration. Rare disease research is expanding the evidence needed to characterize lifelong treatment needs, and regenerative medicine developers are assembling platforms to overcome interconnected technical barriers.
The central competitive question is no longer limited to whether a treatment works. It also concerns which companies can demonstrate durable benefit, reduce practical burdens, and translate clinical advances into accessible care. The answers will depend on reimbursement, real-world outcomes, and execution across different stages of market development.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com